Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $496.59M
• Dividend Yield: N/A
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: 13.17%
• EPS Growth: 64.50%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 381,995,120
• 10 Day Avg. Volume: 1,176,621
• 30 Day Avg. Volume: 1,173,835
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 1.61
• Enterprise Value/Gross Profit: 3.71
• Enterprise Value/Ebitda: -2.72
• 1Y Price Target: $1.55
• Price Target Upside: 19.23% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $1.50 ▲(15.38% Upside)

The overall stock score is primarily influenced by the company's financial struggles, with declining revenues and negative profit margins being significant concerns. Technical analysis provides a neutral outlook, while valuation metrics highlight poor earnings performance. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Low Debt Levels

A low debt-to-equity ratio indicates that the company is not heavily reliant on debt financing, providing financial stability and flexibility to invest in growth opportunities without significant risk of financial distress.

Revenue Growth

Positive revenue growth suggests that the company is expanding its market presence and product adoption, which can lead to increased market share and long-term profitability if sustained.

Strategic Partnerships

Strategic partnerships can drive innovation and expand market reach, enhancing the company's competitive position and opening new revenue streams through collaborative research and development.

Negative Factors

Negative Profit Margins

Negative profit margins indicate that the company is not currently generating sufficient profit from its operations, which can hinder its ability to reinvest in the business and may require cost restructuring to achieve profitability.

Cash Flow Challenges

Negative cash flows suggest difficulties in sustaining operations without external financing, which can limit the company's ability to invest in growth and innovation, potentially impacting long-term competitiveness.

Declining Revenues

A decline in revenues can indicate weakening demand for the company's products or services, which could erode market share and pressure margins if not addressed through strategic initiatives or product innovation.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

How the Company Makes Money

Standard BioTools generates revenue through multiple key streams, primarily by selling its proprietary laboratory instruments, consumables, and software solutions to research institutions, pharmaceutical companies, and clinical laboratories. The company also benefits from ongoing service contracts and maintenance agreements for its equipment, which provide a steady revenue flow. Additionally, Standard BioTools engages in strategic partnerships with academic institutions and industry players, allowing for collaborative research efforts that can lead to innovative product development and expanded market reach. These partnerships often include licensing agreements, which can further enhance the company's revenue potential.

Standard BioTools Financial Statement Overview

Summary

The company faces significant financial challenges with declining revenues and negative profit margins. Despite a low debt-to-equity ratio, profitability and cash flow are under pressure.

Income Statement

The income statement reveals a challenging financial situation with declining revenues and negative profit margins. The TTM data shows a revenue decline of 9.1%, and the net profit margin is significantly negative at -78.1%. Gross profit margin has decreased to 43.3% from 48.3% in the previous year. The company is struggling with profitability as indicated by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.067, indicating low leverage, which is a positive aspect. However, the return on equity is negative at -26.2%, reflecting poor profitability. The equity ratio is not explicitly calculated, but the company maintains a strong equity position relative to its assets.

Cash Flow

Cash flow analysis highlights negative operating and free cash flows, with a free cash flow growth rate of -14.9% TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is above 1, suggesting that free cash flow exceeds net income, which is a positive sign.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	154.24M	174.43M	106.34M	97.95M	130.58M	138.14M
Gross Profit	66.84M	84.26M	50.45M	37.05M	69.37M	83.33M
EBITDA	-91.35M	-118.14M	-54.46M	-173.57M	-43.77M	-32.59M
Net Income	-120.50M	-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet
Total Assets	556.97M	612.34M	323.07M	390.31M	275.21M	324.76M
Cash, Cash Equivalents and Short-Term Investments	237.09M	292.87M	114.89M	165.78M	28.45M	68.52M
Total Debt	28.62M	33.00M	98.21M	102.66M	111.65M	95.38M
Total Liabilities	132.43M	140.62M	159.87M	471.78M	180.62M	185.71M
Stockholders Equity	424.54M	471.72M	163.20M	229.79M	94.60M	139.05M
Cash Flow
Free Cash Flow	-105.46M	-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
Operating Cash Flow	-92.88M	-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
Investing Cash Flow	36.97M	363.17M	20.24M	-88.13M	-11.95M	39.98M
Financing Cash Flow	-54.46M	-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 1.3 is below the 20-day moving average (MA) of 1.33, below the 50-day MA of 1.31, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 47.41 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	63 Neutral	$691.46M	-13.54	-4.57%	―	4.31%	69.57%
CSTL	59 Neutral	$658.78M	-63.85	-2.08%	―	20.40%	-165.41%
CDNA	58 Neutral	$794.68M	14.62	15.79%	―	14.72%	―
MYGN	52 Neutral	$716.44M	-1.80	-101.83%	―	3.83%	-137.31%
PSNL	52 Neutral	$535.61M	-4.75	-47.85%	―	0.36%	22.13%
LAB	48 Neutral	$496.59M	―	-22.40%	―	13.17%	64.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Standard BioTools Corporate Events

Standard BioTools Announces Strategic Restructuring Plan

On August 28, 2025, Standard BioTools Inc. announced a strategic restructuring plan to consolidate its R&D capabilities from South San Francisco to its Singapore facility, aligning with its manufacturing operations. This move, aimed at enhancing operational efficiency and reducing costs, involves a reduction-in-force affecting U.S. employees and is expected to incur expenses of approximately $3.6 million, with potential for additional costs due to unforeseen events.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Announces SomaLogic Sale to Illumina

Standard BioTools reported its financial results for the second quarter of 2025, highlighting a total revenue of $42 million, with $21.8 million from continuing operations. The company announced the strategic sale of SomaLogic to Illumina for up to $425 million, expected to close in the first half of 2026, which will significantly bolster its cash reserves to at least $550 million. This move is part of a broader strategy to streamline operations and focus on profitability by 2026, despite challenges such as reduced U.S. academic spending and global capital constraints. The company is pausing its earnings calls temporarily to focus on operational adjustments.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.